1. Pink Sheet
  2. >>Geography

Japan Recommends Donanemab, Sets Raft Of New And Reduced Prices

Dupixent, Tezspire Slashed

 
• By Lisa Takagi

A Japanese approval for Lilly's Alzheimer's drug donanemab is expected soon following a positive recommendation from the MHLW. The ministry has also announced reimbursement prices for 12 new products including Fabhalta, along with price cuts for Tezspire, Dupixent and competitors following a review.

Japan announced several decisions including new pricing list for NHI and pricing cuts.
Japan sets prices for multiple new drugs, cuts prices of others • Source: Shutterstock

Japan’s Ministry of Health, Labour and Welfare (MHLW) has announced reimbursement prices for a batch of recently approved new drugs under its national health insurance (NHI) scheme.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Japan

More from Asia